Moore Capital Management LP Purchases New Position in Amedisys, Inc. (NASDAQ:AMED)

Moore Capital Management LP purchased a new position in Amedisys, Inc. (NASDAQ:AMED - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 9,000 shares of the health services provider's stock, valued at approximately $817,000.

Other institutional investors also recently bought and sold shares of the company. Trexquant Investment LP raised its stake in Amedisys by 1,317.8% in the fourth quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock worth $7,964,000 after buying an additional 81,532 shares in the last quarter. ABC Arbitrage SA bought a new position in Amedisys in the fourth quarter worth about $2,522,000. Schonfeld Strategic Advisors LLC raised its stake in Amedisys by 17.5% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider's stock worth $409,000 after buying an additional 671 shares in the last quarter. Empowered Funds LLC bought a new position in Amedisys in the fourth quarter worth about $318,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Amedisys during the fourth quarter valued at approximately $590,000. 94.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on AMED shares. Stephens reaffirmed an "equal weight" rating and set a $101.00 target price on shares of Amedisys in a research note on Tuesday, March 4th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $100.00 target price on shares of Amedisys in a research note on Wednesday, April 16th. Four investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $100.75.

Amedisys Stock Up 1.0%

Shares of NASDAQ AMED traded up $0.90 on Friday, reaching $94.62. 440,407 shares of the company's stock traded hands, compared to its average volume of 419,953. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The business's 50 day simple moving average is $93.22 and its two-hundred day simple moving average is $91.66. The company has a market cap of $3.11 billion, a price-to-earnings ratio of 37.55, a price-to-earnings-growth ratio of 1.78 and a beta of 0.96. The company has a quick ratio of 1.19, a current ratio of 1.19 and a debt-to-equity ratio of 0.05.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.13 by $0.12. The company had revenue of $594.78 million during the quarter, compared to the consensus estimate of $597.43 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 earnings per share. As a group, equities research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.